Search the Newsreel

Metagenomi Therapeutics (NasdaqGS:MGX) Stock Forecast & Analyst Predictions

Metagenomi Therapeutics (MGX) faces significant financial challenges, with forecasted declines in revenue and earnings. Analyst consensus shows a downward trend in revenue estimates and price targets, alongside consistent net losses. The company has also experienced volatility in its stock price and is currently facing …

Bionano Genomics (BNGO) Earnings Date and Reports 2026

Enterprise value to EBIT forward of 10x Genomics Inc Class A – BMV:TXG

This article provides financial information for 10x Genomics Inc Class A (BMV:TXG) on TradingView. It specifically highlights the company's enterprise value to EBIT forward metric. The content appears to be a stub or a placeholder page within a larger financial data platform.

Bionano Genomics Inc (BNGO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Bionano Genomics | 8-K: Current report

This article is a current report (8-K filing) from Bionano Genomics. It provides links to two separate documents for more details. The content explicitly states that it is for informational and educational purposes only and does not constitute investment advice.

MFG Wealth Management Inc. Takes Position in NeoGenomics, Inc. $NEO

MFG Wealth Management Inc. has initiated a position in NeoGenomics, Inc. (NASDAQ:NEO) by purchasing 83,462 shares valued at approximately $1.22 million, representing about 0.06% of the company. Institutional investors and hedge funds collectively own 98.5% of NeoGenomics, which has received a "Moderate Buy" consensus …

NeoGenomics Appoints Carolyn Starrett to its Board of Directors

NeoGenomics, Inc. has appointed Carolyn Starrett to its Board of Directors. Ms. Starrett brings over 25 years of experience in commercial, product, and operations roles at data and technology companies, with significant expertise in AI and data insights in cancer care. Her appointment is …

Noticias de acciones de Bionano Genomics Inc (BNGO)

BioNano Genomics Inc (0A4K) Q1 2026 Earnings Report - Results, Call & Slides

BioNano Genomics Inc. (0A4K) reported its Q1 2026 earnings, beating analyst expectations with an EPS of -$0.76 against a consensus of -$0.88 and revenue of $6.69M, surpassing the expected $6.57M. The company highlighted positive operational developments including record flow cell sales, strong consumables growth, …

10x Genomics (TXG) Stock Rally Leans On Margin Gains And Cash

Bionano Genomics, Inc. expected to post a loss of 68 cents a share - Earnings Preview

Bionano Genomics, Inc. is projected to report a loss of 68 cents per share, according to this earnings preview. The article, provided by Refinitiv and featured on TradingView News, offers a brief overview of the upcoming financial expectation for BNGO. Readers can access the …

10x Genomics Q2 Earnings Call Highlights

Key Points Interested in 10x Genomics? Here are five stocks we like better. Atera demand is strong ahead of launch: Booked orders by the end of Q2 exceeded the approximately 40 systems 10x Genomics expects to ship in 2026, with production capacity—not demand—currently limiting …

Neogenomics stock hits 52-week high at 16.46 USD

NeoGenomics Inc. (NEO) stock has reached a 52-week high of $16.46, driven by strong investor confidence and recent positive financial results. Despite being considered overvalued by InvestingPro analysis, the company's stock has delivered a 170% return over the past year, with analysts predicting profitability …

10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up

10x Genomics TXG reported a second-quarter 2026 loss of 14 cents per share against earnings of 28 cents in the year-ago quarter, representing a 150% year-over-year decline. Still, the figure beat the Zacks Consensus Estimate of a loss of 23 cents by 38.1%. Revenues …

NeoGenomics (NEO) Is Up 8.4% After Q2 Profit Return And Raised 2026 Outlook – Has The Bull Case Changed?

NeoGenomics (NEO) reported a return to quarterly profitability in Q2 2026 with revenue of US$201.66 million and a net income of US$2.24 million, a significant improvement from a net loss the previous year. Management also narrowed its expected full-year 2026 net loss and slightly …

Bionano Genomics Inc (BNGO) Stock News Today

This article provides current stock information for Bionano Genomics Inc (BNGO), showing a recent increase of 5.45%. It indicates that more news regarding BNGO's stock, earnings, and analyst ratings will be available soon. The page serves as a hub for financial data and updates …

Metagenomi Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview

Metagenomi Therapeutics Inc is projected to report a loss of 57 cents per share. This earnings preview from Refinitiv indicates the company's expected financial performance. The full article is available on TradingView, offering unlimited access to news from various sources.

BNGO Q2'26 Earnings: EPS estimate is (0.67) USD

Bionano Genomics, Inc. (BNGO) is scheduled to release its Q2'26 financial results on August 10, after market close. The company is expected to report an estimated revenue of $7.55 million and an estimated earnings per share (EPS) of ($0.67) for the quarter. This article …

Dimensional Fund Advisors LP Buys 225,588 Shares of NeoGenomics, Inc. $NEO

Dimensional Fund Advisors LP increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 9.2% in the first quarter, purchasing an additional 225,588 shares, bringing its total holdings to 2.67 million shares valued at approximately $19.8 million. This acquisition reflects a broader institutional interest in NeoGenomics, …

NeoGenomics, Inc. $NEO Stock Position Raised by Sei Investments Co.

Sei Investments Co. significantly increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 320.7% during the first quarter, now holding 466,199 shares valued at $3.46 million. This move is mirrored by other institutional investors, collectively owning 98.5% of the company's stock, despite a recent insider …

How NeoGenomics’ Q2 Profit Return And Higher 2026 Outlook At NeoGenomics (NEO) Has Changed Its Investment Story

NeoGenomics (NEO) reported a return to profitability in Q2 2026 with US$2.24 million net income and raised its full-year 2026 revenue outlook to US$802 million–US$806 million, indicating improving operational performance. This positive shift strengthens the company's investment narrative, emphasizing its role as a specialized …

NeoGenomics, Inc. Revenue Breakdown – BX:NG9

NeoGenomics, Inc. (BX:NG9) generated 576.61 million CHF in revenue last year. The "Client Direct Billing" segment was the top performer, contributing 411.32 million CHF, a decrease from the previous year. The United States was the primary regional contributor, accounting for all of the company's …

10x Genomics raises 2026 revenue outlook to $610M-$630M as Atera shipments remain about 40 units

Earnings Call Insights: 10x Genomics (TXG) Q2 2026 MANAGEMENT VIEW * "Revenue for the second quarter was $151 million" (CEO Serge Saxonov) and management highlighted a nonrecurring item: "we recognized $1.6 million of license and royalty revenue in connection with our settlement with Takara" …

Edding Genor Advances GB268 Breast Cancer Trial with First Patient Dosed

10x Genomics’s (NASDAQ:TXG) Q2 CY2026: Strong Sales, Full-Year Outlook Slightly Exceeds Expectations

10x Genomics (NASDAQ: TXG) grows consumables, ends Q2 with $502M cash

10x Genomics reported a Q2 2026 total revenue of $151.0M, a 13% decrease from Q2 2025, primarily due to the absence of large, non-recurring patent-license settlements from the previous year. Despite this, underlying products and services revenue grew by 3% to $149.1M, driven by …

10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

10X GENOMICS ($TXG) Releases Q2 2026 Earnings

10x Genomics (NASDAQ: TXG) swings to Q2 loss but lifts 2026 revenue guide

10x Genomics Reports Second Quarter 2026 Financial Results

10x Genomics, Inc. (TXG) stock price, news, quote and history

This Yahoo Finance page provides a comprehensive overview of 10x Genomics, Inc. (TXG), including its current stock price, recent news, chart performance over various periods, and key financial data. The article details the company's products and services, such as the Chromium and Visium platforms …

10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

Bionano Genomics (BNGO) grants 5,000 options to officer

Bionano Genomics (BNGO) reported that its Principal Accounting Officer, Mark Adamchak, received a grant of 5,000 stock options. These options have an exercise price of $1.12 per share, vest 50% on the first and second anniversaries of the vesting commencement date, and expire on …

Bionano Genomics (NASDAQ: BNGO) awards 15,000 options to its general counsel

Bionano Genomics (NASDAQ: BNGO) has granted 15,000 stock options to its General Counsel, Jonathan V. Dixon, on August 3, 2026. The options have an exercise price of $1.12 per share and will expire on August 2, 2036. These options vest 50% on each of …

Bionano Genomics, Inc. (BNGO) CSO lists 54,000-share stock option position

Bionano Genomics, Inc. (BNGO) Chief Scientific Officer Hastie Alex Reid has reported a stock option to buy 54,000 shares of common stock at an exercise price of $1.12 per share, expiring on August 2, 2036. The vesting schedule includes 25% of the shares becoming …

MGX|Metagenomi Inc|Price:1.215|Chg%:+0.005

Metagenomi Inc (MGX) has a TradingKey Stock Score indicating stable fundamentals and significant growth potential, although its valuation is considered fairly valued within the Biotechnology & Medical Research industry. The company, focused on precision genetic medicine, has seen high institutional ownership and multiple "Buy" …